Treatment of menorrhagia with mazu
Phase 2
Not yet recruiting
- Conditions
- Health Condition 1: N920- Excessive and frequent menstruation with regular cycle
- Registration Number
- CTRI/2022/05/042871
- Lead Sponsor
- uqman Unani Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Married women of 18 to 40 years of age
Regular menses
PBAC score above 100
Exclusion Criteria
Pregnant and lactating women
Severe anemia and blood dyscrasias
Organic pelvic pathology
Systemic and metabolic illnesses
Recent history of dengue and chicken guinea
Women on anticoagulants OCPs and having IUCDs
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Mazu Quercusinfectoria target in treating menorrhagia?
How does Mazu Quercusinfectoria compare to standard-of-care treatments for N920 menorrhagia?
Are there specific biomarkers that predict response to Mazu Quercusinfectoria in menstrual disorders?
What are the potential adverse events associated with Mazu Quercusinfectoria in clinical trials?
What related compounds or combination therapies are being explored for menorrhagia alongside Mazu Quercusinfectoria?